Valeant Pharmaceuticals "Driving Innovation at Bausch + Lomb" Presentation from OIS@ASCRS 2015

1. Driving Innovation at
Bausch + Lomb
J. Michael Pearson
Chairman and CEO
Valeant Pharmaceuticals International, Inc.

2. 2
PROLENSA® (bromfenac ophthalmic solution) 0.07%
Lotemax® (loteprednol etabonate ophthalmic gel) 0.5%
Soothe® XP-Xtra Protection Emollient (Lubricant) Eye Drops
Soothe® Long Lasting Lubricant Eye Drops
VICTUS® Femtosecond Laser Indications
enVista® IOL
Trulign® Toric IOL
Stellaris® PC valved trocars
Stellaris® PC integrated laser for vitreoretinal surgery
PureVision® 2 Multi-Focal Contact Lenses for Presbyopia
Biotrue® ONEday Contact Lenses
Biotrue® ONEday Contact Lenses for Presbyopia (low add)
Bausch + Lomb ULTRA® Contact Lenses
PeroxiClear® 3% Hydrogen Peroxide Cleaning & Disinfecting Solution
PreserVision® Eye Vitamin AREDS 2 Formula
Eye Health Launches in the Past Two Years

3. 3
Launches Expected in the Next Two Years
 Spectrus Navigation™ Surgical System
 Vitesse™ Novel Vitrectomy Instrument Technology
 enVista® Toric Intraocular Lenses
 Stellaris® PC System Chandelier Lighting
 Latanoprostene bunod
 Luminesse™* Eye Drops
 Sub-micron Particle Loteprednol
 Biotrue® ONEday Contact Lenses for Asigmatism
 Biotrue® ONEday Contact Lenses for Presbyopia (high add)
 Bausch + Lomb ULTRA® Contact Lenses for Astigmatism
 Bausch + Lomb ULTRA® Contact Lenses for Presbyopia
 Bausch + Lomb ULTRA® Contact Lenses SVS Plus Powers
* Tentatively approved name

4. 4
RetinaCataract Glaucoma Cornea
Uveitis Myopia Optics
Exciting Innovative Research

5. 5
Three Pathways to Innovation
Internal
Development
• Stellaris® PC
• PureVision®2 Multi-Focal
• Biotrue® ONEday
• Bausch + Lomb ULTRA®
• PeroxiClear®
• Vitesse™
Acquired
Companies
• Victus®
• Teneo™ Excimer Laser
• Prolensa®
• Crystalens®
• Trulign®
• Sjö® Diagnostic Test Kit
Licensed
Technologies
• Lotemax® Gel
• Latanoprostene bunod
• Soothe® XP
• Luminesse™*
• enVista®
• Spectrus Navigation™
* Tentatively approved name

6. 6
Innovation Philosophy
 Not “one way” to develop innovative products
 Flexible, nimble approach to R&D
 Each project evaluated based on merits, not
origin
 Every promising R&D project has been advanced
 Extensive Bausch + Lomb pipeline
 85 physicians as full time employees in US alone
 Includes longer-term projects with development
partners

7. 7
Future of Ophthalmic Industry
Multiple-function technologies
- Victus® femtosecond laser
• Cataract surgery capabilities
• LASIK flaps
- Stellaris® PC System
• Cataract surgery capabilities
• Vitreoretinal surgery capabilities
Accelerating
pressure to
reduce cost
and increase
efficiency of
medical care
Industry Trend Bausch + Lomb Pipeline Response

8. 8
Future of Ophthalmic Industry
Compliance-supporting innovations
- Latanoprostene bunod
• Targeted to reduced overnight
pressure spikes
• Targeted to improve 24 hour IOP
control
- Sub-micron particle loteprednol
• Potential for less frequent dosing
Outcomes
become a
greater factor in
reimbursement
Industry Trend Bausch + Lomb Pipeline Response

9. 9
Future of Ophthalmic Industry
Target patients in their 40’s and 50’s
- Bausch + Lomb ULTRA® Contact Lenses
• Addition of presbyopia model
- Crystalens® and Trulign® Toric IOLs
- Excimer laser
Presbyopia solutions including the
following: - Lens based surgery
- Cornea based surgery
- Contact lenses
Presbyopia
correction will
continue to be a
market driver
Industry Trend Bausch + Lomb Pipeline Response

10. 10
Summary
 Important link between an innovative product
offering and company financial performance
 Indifferent to the origin of product innovations –
internal, licensed, acquired
 Disciplined approach to R&D project selection
 Focused on R&D output, not spending targets
 Bausch + Lomb is your preferred partner
 You are the greatest source of ideas and
innovations

11. 11
US/PRA/15/0027®/TM are trademarks of Valeant Pharmaceuticals International, Inc. or its affiliates.
© Bausch & Lomb Incorporated.